Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTheriva Biologics Inc.

Theriva Biologics Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.1591 USD -0.01 ( 4.44%)
Last update at 2026-11-09T18:10:00Z
VOLUME
502495
Market Cap
10.33M
P/E
0.16

Momentum Score

…

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.16
Low
0.17
High
52 Week Price Range
0.16
Low
0.86
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Theriva Biologics Inc. is a publicly traded company that identifies as a biologics firm, but public disclosures about its operations and programs are limited. Long-term growth drivers may include advancement of any product candidates, regulatory milestones, strategic collaborations and successful commercialization if applicable, which could support value creation. Investors may find exposure to potential upside in the biotechnology sector attractive despite elevated information risk.

Key investment risks include limited public information, probable early-stage development with significant regulatory and execution uncertainty, funding needs and low trading liquidity that could increase volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.17
Dividend Yield
-
Revenue TTM
0.30M
Revenue Per Share
0.01
Gross Profit TTM
0.30M
Debt / Equity
0.17
ROE
-101.87%
Net Debt
-10.43M
ROCE
-84.11%
Diluted EPS TTM
1.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -23.74M -25.65M -19.99M -21.11M -14.27M
Minority interest - - - 0.00M 0.00M
Net income -25.25M -25.65M -18.35M -19.68M -14.17M
Selling general administrative 15.45M 7.40M 7.16M 9.86M 6.47M
Selling and marketing expenses - - 0.62M - -
Gross profit -0.11M -0.14M -0.14M - -
Reconciled depreciation 0.11M 0.14M 0.12M 0.09M 0.09M
Ebit -23.74M -19.43M -22.09M -21.58M -14.36M
Ebitda -23.63M -19.29M -21.96M -21.45M -14.27M
Depreciation and amortization 0.11M 0.14M 0.14M 0.13M 0.09M
Operating income -15.02M -26.35M -21.43M -21.58M -14.27M
Other operating expenses 15.02M 26.35M 21.43M 21.58M 14.27M
Interest expense - - - -0.43M 0.09M
Tax provision 0.00M 0.00M -1.77M -1.43M -
Interest income 0.29M 0.70M 1.44M 0.51M 0.01M
Net interest income 0.29M 0.70M 1.44M 0.51M 0.01M
Income tax expense 1.51M - -1.64M -1.43M -0.09M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 14.91M 26.35M 21.43M 21.58M 14.27M
Cost of revenue 0.11M 0.14M 0.14M - -
Total other income expense net -8.72M 0.69M 1.44M 0.47M 0.01M
Net income from continuing ops -23.74M -25.65M -19.31M -19.68M -14.27M
Net income applicable to common shares - - - -19.68M -23.19M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 38.24M 35.35M 55.22M 71.86M 70.36M
Intangible assets 19.62M 17.36M 19.75M 19.15M -
Other current assets 0.58M 1.35M 2.29M 3.73M 1.53M
Total liab 22.86M 16.29M 15.52M 17.30M 4.96M
Total stockholder equity 15.38M 19.07M 39.70M 54.56M 65.41M
Deferred long term liab - - - 19.15M -
Other current liab 8.39M 6.13M 5.42M 5.87M 2.91M
Common stock 0.03M 0.00M 0.02M 0.02M 0.13M
Capital stock 0.03M 0.00M 2.75M 2.75M 0.13M
Retained earnings -358.71M -334.97M -309.32M -290.97M -271.28M
Other liab - - - 8.83M -
Good will - 0.00M 5.70M 5.53M -
Other assets - - - 19.27M 0.02M
Cash 13.06M 11.61M 23.18M 41.79M 67.33M
Total current liabilities 10.01M 7.58M 6.74M 7.06M 3.55M
Current deferred revenue - - 2.87M - -
Net debt -10.43M -10.04M -21.02M -40.10M -65.80M
Short term debt 0.61M 0.60M 0.55M 0.27M 0.12M
Short long term debt 0.06M 0.06M 0.06M 0.06M -
Short long term debt total 2.63M 1.56M 2.15M 1.68M 1.53M
Other stockholder equity 373.30M 355.21M 346.23M 343.46M 336.56M
Property plant equipment - - - 1.54M 1.48M
Total current assets 17.47M 16.28M 27.40M 45.52M 68.86M
Net tangible assets - - - 46.30M 65.41M
Net receivables 3.83M 3.32M 1.94M 0.23M -
Long term debt 1.67M 0.09M 0.16M 0.22M -
Inventory - - - -0.23M -
Accounts payable 1.01M 0.86M 0.77M 0.92M 0.52M
Accumulated other comprehensive income 0.76M -1.18M 0.03M -0.68M -
Non currrent assets other 0.08M 0.17M 0.08M 0.12M 0.02M
Non current assets total 20.77M 19.07M 27.82M 26.34M 1.51M
Capital lease obligations 0.90M 1.41M 1.93M 1.40M 1.53M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.00M -0.24M -4.40M -0.01M
Change to liabilities - - - -0.39M -0.36M
Total cashflows from investing activities -0.04M -0.00M -0.20M -4.40M -0.01M
Net borrowings 1.44M -0.07M -0.07M - -
Total cash from financing activities 18.19M 5.50M 0.62M -1.93M 74.00M
Change to operating activities - - - -0.24M 1.24M
Net income -23.74M -25.65M -18.35M -19.68M -14.27M
Change in cash 1.40M -11.57M -18.61M -25.44M 61.10M
Begin period cash flow 11.71M 23.28M 41.88M 67.33M 6.23M
End period cash flow 13.10M 11.71M 23.28M 41.88M 67.33M
Total cash from operating activities -16.67M -16.94M -19.00M -19.08M -12.89M
Issuance of capital stock 13.52M 5.56M 2.16M 2.73M 65.96M
Depreciation 0.11M 0.14M 0.14M 0.09M 0.09M
Sale purchase of stock - - 0.00M -0.29M -
Other cashflows from financing activities 3.23M 5.50M -1.52M -2.27M 8.04M
Change to netincome - - - 1.14M 0.41M
Capital expenditures 0.04M 0.00M 0.20M 0.12M 0.01M
Change in working capital -3.06M 0.73M 2.31M -0.81M 0.88M
Stock based compensation 0.65M 0.67M 0.55M 0.47M 0.42M
Other non cash items 9.37M 8.07M -2.00M 2.27M -
Free cash flow -16.70M -16.94M -19.20M -19.20M -12.90M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TOVX
Theriva Biologics Inc.		 -0.01
4.44%		 0.16 0.16 - 34.43 0.89 10.09 1.72
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Theriva Biologics Inc.

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

9605 Medical Center Drive, Rockville, MD, United States, 20850

301 417 4364

https://therivabio.com

15

Name Title Year Born
Mr. Steven A. Shallcross CPA CEO, CFO, Treasurer, Corp. Sec. & Director 1961
Dr. Frank Tufaro Ph.D. Chief Operating Officer 1955
Vincent I. Perrone Director of Corp. Communication NA
Dr. Vince Wacher Ph.D. Head of Product and Corp. Devel. NA
Dr. Michael Kaleko M.D., Ph.D. Sr. VP of R&D NA
Ms. Lara M. Guzman Sr. Director of Project Operations NA
Mr. Steven A. Shallcross CPA CEO, CFO, Treasurer, Corporate Secretary & Director 1961
Dr. Vince Wacher Ph.D. Senior Vice President of Corporate & Product Development NA
Dr. Ramon Alemany Ph.D. Senior Vice President of Discovery NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.22%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.64%

  • Healthcare

    +1.58%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…